Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Some people are fair-weather friends; others are lifelong. It's a similar story with stocks. Some you might hold only ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

it's about as confident tone as you can expect from or as you'd want from a management team," said Kevin Gade, chief operating officer at Bahl & Gaynor, which owns Lilly's shares. Eli Lilly also ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Eli Lilly guided up to 2025 revenue of $58 to $61 billion, with analysts currently just above $58 billion. The guidance predicts sales growth of 32% for the year, and the management team actually ...